On December 22, 2025, the U.S. Food and Drug Administration approved Wegovy as a once-daily pill — the first oral GLP-1 cleared for chronic weight management in adults with obesity (or overweight with at least one weight-related condition). Novo Nordisk is also putting a second flag on the label: the pill version is indicated to reduce the risk of major adverse cardiovascular events in adults with overweight or obesity who already have cardiovascular disease.
That sounds like a simple format change — from needle to tablet. In practice, it changes at least four things at once: who shows up to treatment,
